Skip to search formSkip to main contentSkip to account menu

Vincristine sulfate liposome

Known as: vincristine sulfate liposomes 
A sphingomyelin/cholesterol liposomal formulation of vincristine sulfate with potential antineoplastic activity. Vincristine, a vinca alkaloid… 
National Institutes of Health

Related topics

Related topics

8 relations

Narrower (2)

MarqiboOnco TCS
Microtubule ProcessMicrotubulesNegative Regulation of MitosisTubulin

Broader (2)

Vincristine Sulfatevincristine liposome

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A ready-to-use formulation for vincristine sulfate liposome injection
Disclosed herein are various compositions comprising neoplastic formulations and their methods of use. 
2015
2015
Marqibo®, Vincristine Sulfate Liposome Injection, for the Treatment of Advanced, Relapsed or Refractory Philadelphia Chromosome-Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) in an Adolescent…
Background : Patients aged 15 to 39 years old constitute the Adolescent Young Adult (AYA) population. In the US, leukemias… 
2013
2013
High-Dose Vincristine Sulfate Liposome Injection (Marqibo®) Is Not Associated With Clinically Meaningful Hematologic Toxicity
Background The treatment of hematologic malignancy patients with heavily pre-treated, advanced, relapsed, or refractory disease… 
2013
2013
It's ALL in the liposomes: vincristine gets a new package.
In 1963, the US Food and Drug Administration approved vincristine at a dose of 1.4 mg/m, and almost 50 years later on August 9… 
2013
2013
Determination of free and total vincristine in human plasma after intravenous administration of vincristine sulfate liposome injection using ultra-high performance liquid chromatography tandem mass…
2013
2013
Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo®) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated…
Introduction Despite significant advances over the past decade in the treatment of CD20+ aggressive Non-Hodgkin Lymphomas (NHL… 
2010
2010
Marqibo® (vincristine sulfate liposomes injection; VSLI) In the Treatment of Adult Patients with Advanced, Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL): A Combined Analysis of the VSLI-06…
Abstract 2143 Background: The outcome of adults with relapsed/refractory ALL, and of those whose disease recurs after first… 
2009
2009
Phase II study of vincristine sulfate liposomes injection in patients with metastatic uveal melanoma.
9067 Background: Preclinical and clinical studies showed that liposomal encapsulation of vincristine sulfate (VCR) results in… 
2009
2009
Pivotal Phase 2 Study of Weekly Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®) in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or…
Abstract 3088 Poster Board III-25 Adult ALL is a disease of primarily young and middle-aged adults that is associated with a high… 
2007
2007
Marqibo (Vincristine Sulfate Liposomes Injection, OPTISOME™) Concentrates Vincristine in Tumor Tissue and Lymphoid Malignancy Oriented Tissues in Tumor-Bearing Mice.
Background: Vincristine sulfate (VCR) is a cell-cycle specific, lipophilic, anti-cancer drug that inhibits cell division by… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)